Allakos Inc. (ALLK)
After hours:
| Previous close | 7.85 |
| Open | 7.75 |
| Bid | 7.59 x 800 |
| Ask | 7.67 x 1800 |
| Day's range | 7.44 - 7.96 |
| 52-week range | 7.44 - 157.98 |
| Volume | |
| Avg. volume | 4,068,533 |
| Market cap | 414.954M |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.14 |
| Earnings date | 28 Feb 2022 - 04 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 56.20 |
- Simply Wall St.
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- Motley Fool
Why Allakos Stock Plummeted 87.5% in the Last Month of 2021
Allakos published phase 3 Enigma 2 and phase 2/3 Kryptos trial data on its lirentelimab monoclonal antibody as a treatment for eosinophilic gastrointestinal diseases (EGIDs), and the results shocked the market. Lirentelimab had shown promising results as a treatment for eosinophilic gastrointestinal diseases in its phase 2 trials, and the phase 3 data caught the market off guard. The crushing study results were followed by a series of downgrades from high-profile analysts.
- Zacks
Down 86.1% in 4 Weeks, Here's Why Allakos Inc. (ALLK) Looks Ripe for a Turnaround
Allakos Inc. (ALLK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
